⌘K
Loading ticker…
As of 2026-08-24, Aprea Therapeutics, Inc. Common stock (APRE) has a 3-month relative strength percentile of 24 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 41. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 8.7%, relative volume 59.16×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
APRE appears in 1 ETF as of Mar 2026: VXF at 0.00% weight, $15K notional.
Held by 1 ETFs · $15K across latest filings · largest weight 0.00% (VXF).
Top 1 by value, from SEC N-PORT-P filings dated Mar 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VXFVanguard Extended Market ETF | 0.00% | $15K | — |
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Weak relative strength and quiet attention. Little to read here either way.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
News
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | APRE Jan avg: 18.42% median: 14.42% win: 75% σ: 24.47% n: 4 2022-04-12 → 2026-07-31 | APRE Feb avg: -1.31% median: -10.02% win: 50% σ: 51.31% n: 4 2022-04-12 → 2026-07-31 | APRE Mar avg: -17.66% median: -18.13% win: 0% σ: 3.29% n: 4 2022-04-12 → 2026-07-31 | APRE Apr avg: -12.91% median: -14.71% win: 20% σ: 11.12% n: 5 2022-04-12 → 2026-07-31 | APRE May avg: -8.08% median: -2.90% win: 40% σ: 20.47% n: 5 2022-04-12 → 2026-07-31 | APRE Jun avg: -11.26% median: -10.45% win: 0% σ: 5.74% n: 5 2022-04-12 → 2026-07-31 | APRE Jul avg: -1.35% median: -1.59% win: 40% σ: 18.82% n: 5 2022-04-12 → 2026-07-31 | APRE Aug avg: -2.79% median: -6.61% win: 25% σ: 15.63% n: 4 2022-04-12 → 2026-07-31 (current) | APRE Sep avg: -7.77% median: -11.95% win: 25% σ: 14.96% n: 4 2022-04-12 → 2026-07-31 | APRE Oct avg: 5.20% median: -1.01% win: 50% σ: 26.34% n: 4 2022-04-12 → 2026-07-31 | APRE Nov avg: -16.39% median: -17.92% win: 25% σ: 20.09% n: 4 2022-04-12 → 2026-07-31 | APRE Dec avg: -2.49% median: -3.40% win: 50% σ: 28.62% n: 4 2022-04-12 → 2026-07-31 |